A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm!
The opioid epidemic is the most important and most serious public health crisis today. The effects are reported in overdose deaths but are also starkly evident in declines in sense of well-being and general health.As per most recent research, JEC analysis has found that the opioid epidemic has cost the U.S. nearly $1.5 trillion in 2020, and this figure is likely increasing each year! As the Opioid crisis continues to claim lives, Scilex Holding Company (NASDAQ: SCLX) is addressing the problem with promising solutions and already has 3 FDA approved offerings under its belt!
SCLX is focused on developing non-opioid pain management products and is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. SCLX already has THREE commercialized products that are already FDA APPOVED and three are in development and could be inching towards FDA approval too! A few other big reasons to have your eyes on this rising healthcare firm include a $5.50 price target from Zacks SCR and a HEAVY short interest of 12.71M shares (As of 11/1/24). There could be an imminent short squeeze ahead for this small cap NASDAQ company!
